Evaxion Biotech Stock Discussion

$Evaxion Biotech(EVAX.US)$     Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method.                  Evaxion, On Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method, Says An International Preliminary Report on Patentability Indicates 'Promising Prospects for Obtaining Granted Patents and Protecting the Invention'

$Evaxion Biotech(EVAX.US)$ Evaxion Biotech A/S: One-Year Clinical Efficacy Readout From Phase 2 Study Is on Track for Q3 2024

$Evaxion Biotech(EVAX.US)$
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
Evaxion has published Phase 1 study data for its AI-designed personalized cancer vaccine, EVX-01, in the Journal for ImmunoTherapy of Cancer. The study showed a 67% objective response rate (ORR) in patients with metastatic melanoma, with eight out of 12 patients showing clinical responses — six partial...

$Evaxion Biotech(EVAX.US)$ Evaxion Presents Positive and Validating Immune Data From Ongoing Phase 2 Trial With AI-Designed Evx-01 Vaccine at the Asco Annual Meeting 2024

$Evaxion Biotech(EVAX.US)$
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
JUNE 01, 2024
Poster Details:
Abstract Title:“Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma”
Abstract #:9561
Poster Bd #:345 
Track:Melanoma/Skin Cancers
Location:Hall A – McCormick Pla...

$Evaxion Biotech(EVAX.US)$ Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

$Evaxion Biotech(EVAX.US)$ Evaxion's EVX-B1 Vaccine Shows Promising Protection Against Staph Infections in Preclinical Studies.
MT Newswires· 1 min ago

$Evaxion Biotech(EVAX.US)$ Evaxion Biotech beat estimated earnings by 90.0%, that's great news!!

$Evaxion Biotech(EVAX.US)$ Great R&D Day presentation this afternoon at Evaxion headquaters. Looks like 24-25 will be great years, and the possibilities with these AI models will most definitely break grounds and push up. 🙌